OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) shares advanced 36.57% to $0.915 on Friday and stayed unchanged in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.95. The company has a market cap of $128.82 million at 135.31 million shares outstanding.
Last week, OWC Pharmaceutical Research Corp nnounced that it will be presenting at the Wall Street Conference. The event will be held at the Hilton Doubletree Hotel and Conference Center in Deerfield Beach/ Boca Raton, Florida, on Wednesday, March 1, 2017. This is the premiere conference in the venture capital arena and small-cap marketplace and participants include industry leaders from the hedge fund, investment banking, and private equity worlds.
The company is scheduled to give its presentation on or around 3:30 PM, as a follow to its advisory board member, Jeffery Friedland’s key tone session. Friedland is a member of the company’s Advisory Board and is also CEO of Intiva Inc., which was an early-stage investor in OWC.
“The legal cannabis market has expanded considerably over the past two years, generating significant and growing investor interest. However, there are only a handful of publicly-traded companies focused on cannabinoid-based, pharmaceutical development and a true scientific approach to product development. I intend to discuss what I see as the publicly-traded cannabis opportunities at the Conference,” he remarked.
Prior to this, OWC Pharmaceutical Research Corp announced the appointment of Dr. Sharon Rozenblat as Senior Advisor to the Scientific Advisory Board of its wholly-owned Israeli subsidiary, One World Cannabis Ltd. As such, she will be tasked with overseeing the completion of the pre-clinical safety studies on the company’s treatment for psoriasis, which commenced in November 2016 and steering the company’s efforts to commercialize OWC’s cannabis-based formulations and delivery mechanisms.
“Dr. Rozenblat has had a significant impact in the field of dermatology, specifically with regard to botanical formulations. With more than 15 years’ experience in the research and development of herbal extracts and related products, as well as considerable experience in the design and management of clinical trials, she is the perfect complement to our scientific team,” remarked the company’s Chief Scientific Officer Dr. Yehuda Baruch.
OWC Pharmaceutical Research Corp is a medical cannabis research and development company that is engaged in the research and development of cannabis-based medical products for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. It also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder migraines and a delivery system.